SEC Form SC 13G/A filed by Decibel Therapeutics Inc. (Amendment)

$DBTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $DBTX alert in real time by email
SC 13G/A 1 tm233236-8_sc13ga.htm SC 13G/A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G*

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

(Amendment No. 2)*

 

 

Decibel Therapeutics, Inc.
(Name of Issuer)
 
Common Stock, $0.001 par value per share (the “Shares”)
(Title of Class of Securities)
 
24343R106
(CUSIP Number)
 
December 31, 2022
(Date of Event Which Requires Filing of the Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

CUSIP No. 24343R106 13G Page 2 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Advisors LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

1,770,189 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.1%1

12.

TYPE OF REPORTING PERSON

 

IA; OO; HC

       

 

_________________________

1 The percentages reported in this Schedule 13G are based upon 24,964,502 Shares outstanding as of November 1, 2022 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 9, 2022).

 

 

 

 

 

CUSIP No. 24343R106 13G Page 3 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Advisors Holdings LP

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

1,770,189 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.1%

12.

TYPE OF REPORTING PERSON

 

PN; HC

       

 

 

 

 

 

CUSIP No. 24343R106 13G Page 4 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel GP LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

1,770,189 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.1%

12.

TYPE OF REPORTING PERSON

 

OO; HC

       

 

 

 

 

 

CUSIP No. 24343R106 13G Page 5 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Securities LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

93,222 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.4%

12.

TYPE OF REPORTING PERSON

 

BD; OO

       

 

 

 

 

 

CUSIP No. 24343R106 13G Page 6 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Securities Group LP

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

93,222 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.4%

12.

TYPE OF REPORTING PERSON

 

PN; HC

       

 

 

 

 

 

CUSIP No. 24343R106 13G Page 7 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Securities GP LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

93,222 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.4%

12.

TYPE OF REPORTING PERSON

 

OO; HC

       

 

 

 

 

 

CUSIP No. 24343R106 13G Page 8 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Kenneth Griffin

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

U.S. Citizen

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

1,863,411 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.5%

12.

TYPE OF REPORTING PERSON

 

IN; HC

       

 

 

 

 

 

CUSIP No. 24343R106 13G Page 9 of 13 Pages

 

 

Item 1(a). Name of Issuer:
   
  Decibel Therapeutics, Inc.
   
Item 1(b). Address of Issuer’s Principal Executive Offices:
   
  1325 Boylston Street, Suite 500, Boston, MA 02215 United States 
   
Item 2(a). Name of Person Filing:
   
  This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (“CM”), and Citadel Securities.  Such owned Shares may include other instruments exercisable for or convertible into Shares.
   
  Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities.  CSGP is the general partner of CALC4.  Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
   
  The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
   
Item 2(b). Address or Principal Business Office or, if none, Residence:
   
  The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
   
Item 2(c). Citizenship:
   
  Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware.  Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware.  Mr. Griffin is a U.S. citizen.
   
Item 2(d). Title of Class of Securities:
   
  Common Stock, $0.001 par value per share
   
Item 2(e). CUSIP Number:
   
  24343R106

 

 

 

 

 

CUSIP No. 24343R106 13G Page 10 of 13 Pages

 

 

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
   
  (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
  (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
  (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
  (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
         
  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
         
Item 4. Ownership:
         
  A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
         
    (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 1,770,189 Shares.
         
    (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 7.1% of the Shares outstanding.
         
    (c) Number of Shares as to which such person has:
         
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  1,770,189
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  1,770,189

 

 

 

 

 

CUSIP No. 24343R106 13G Page 11 of 13 Pages

 

 

  B. Citadel Securities LLC
         
    (a) Citadel Securities LLC may be deemed to beneficially own 93,222 Shares.
       
    (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.4% of the Shares outstanding.
       
    (c) Number of shares of Shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  93,222
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  93,222
         
  C. Citadel Securities Group LP and Citadel Securities GP LLC
         
    (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 93,222 Shares.
       
    (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.4% of the Shares outstanding.
       
    (c) Number of Shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  93,222
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  93,222
         

 

 

 

 

 

CUSIP No. 24343R106 13G Page 12 of 13 Pages

 

 

  D. Kenneth Griffin
         
    (a) Mr. Griffin may be deemed to beneficially own 1,863,411 Shares.
       
    (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 7.5% of the Shares outstanding.
       
    (c) Number of Shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  1,863,411
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  1,863,411

 

Item 5. Ownership of Five Percent or Less of a Class:
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. o
   
Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
   
  Not Applicable
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
   
  Not Applicable
   
Item 8. Identification and Classification of Members of the Group:
   
  Not Applicable
   
Item 9. Notice of Dissolution of Group:
   
  Not Applicable
   
Item 10. Certifications:
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

 

CUSIP No. 24343R106 13G Page 13 of 13 Pages

 

 

SIGNATURE

 

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated February 14, 2023.

 

CITADEL SECURITIES LLC   CITADEL ADVISORS LLC  
           
By: /s/ Guy Miller   By: /s/ Sean McHugh  
  Guy Miller, Authorized Signatory     Sean McHugh, Authorized Signatory  
           
           
CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP  
           
By: /s/ Guy Miller   By: /s/ Sean McHugh  
  Guy Miller, Authorized Signatory     Sean McHugh, Authorized Signatory  
           
           
CITADEL SECURITIES GP LLC   CITADEL GP LLC  
           
By: /s/ Guy Miller   By: /s/ Sean McHugh  
  Guy Miller, Authorized Signatory     Sean McHugh, Authorized Signatory  
           
           
      KENNETH GRIFFIN  
           
      By: /s/ Sean McHugh  
        Sean McHugh, attorney-in-fact*  

 

 

_________________________

* Sean McHugh is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein.  The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Gores Holdings VIII, Inc. on March 18, 2022.

 

 

 

 

 

Get the next $DBTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DBTX

DatePrice TargetRatingAnalyst
3/15/2023$7.00 → $2.00Outperform → Market Perform
SVB Securities
12/2/2021$25.00Buy
JonesTrading
11/15/2021$23.00Buy
HC Wainwright & Co.
11/10/2021$15.00 → $14.00Outperform
SVB Leerink
10/22/2021$21.00Outperform
Robert W. Baird
10/22/2021$21.00Outperform
Baird
More analyst ratings

$DBTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • Lifshitz Law PLLC Announces Investigations of WMC, MITT, DBTX, and CTG

    NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Western Asset Mortgage Capital Corporation (NYSE:WMC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of WMC to AG Mortgage Investment Trust, Inc. Under the terms of the proposed merger, WMC shareholders will receive 1.5 shares of AG Mortgage Investment Trust, Inc. for each share of WMC common stocked owned and a cash payment from Angelo Gordon equal to approximately 9.99% of the aggregate per share merger consideration (not to exceed $7 million in total). If you are a WMC investor, and would like additional information about our investigation, please complete the Information R

    $CTG
    $DBTX
    $MITT
    $WMC
    EDP Services
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Decibel Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Update

    - Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 - - Received FDA Breakthrough Therapy Designation for DB-020 for protection against hearing loss associated with cisplatin chemotherapy - - Announced on August 9 definitive agreement for Regeneron Pharmaceuticals to acquire Decibel - BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financi

    $DBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs

    Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel's lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Decibel Therapeutics, Inc. (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of

    $DBTX
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DBTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$DBTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$DBTX
SEC Filings

See more

$DBTX
Leadership Updates

Live Leadership Updates

See more
  • Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

    - Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the Phase 1/2 clinical trial to the U.K. and Spain in patients two years of age and younger - - Initiated manufacturing activities to support IND-enabling studies for our AAV.103 product candidate designed to restore hearing in individuals with mutations in the GJB2 gene - BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing

    $DBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors

    BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its Board of Directors. "We are pleased to welcome Matt to the Decibel Board. He is an accomplished life sciences executive who has played a key role in advancing gene therapy products from the laboratory to patients in need," said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. "Matt's appointment to the Board provides us with a critical strategic perspective, as we continue to build Decibel and lead

    $DBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

    - Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients - - Plan to initiate the CHORD™ trial in the First Half of 2023 - - Presented key non-clinical data at the 46th Annual ARO MidWinter Meeting supporting compelling safety profile of DB-OTO and preclinical data supporting selection of AAV.103 product candidate - BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial result

    $DBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$DBTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more